Filing Flows › Aligos Therapeutics (ALGS) › Takeover & LBO
Is Aligos Therapeutics (ALGS) a takeover target?
A leveraged buyout does not work for Aligos Therapeutics on its latest figures: it has no positive EBITDA to borrow against (−$77.9M over the last 12 months, on revenue of $3.7M).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Aligos Therapeutics' EBITDA over the last 12 months was −$77.9M on revenue of $3.7M, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Aligos Therapeutics would cost about $7.21 a share, $75.2M for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $6.51 | $68.0M |
| Median | 35% | $7.21 | $75.2M |
| High end (a quarter paid more) | 45% | $7.74 | $80.8M |
Aligos Therapeutics' latest quarter
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
Questions
Is Aligos Therapeutics being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Aligos Therapeutics?
A leveraged buyout does not work for Aligos Therapeutics on its latest figures: it has no positive EBITDA to borrow against (−$77.9M over the last 12 months, on revenue of $3.7M). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Aligos Therapeutics cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Aligos Therapeutics would cost about $7.21 a share, $75.2M for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.